Rheumatology Medical News about APS, Phosphatidylethanolamine, Lupus

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome
Lupus, 08/17/09

Sanmarco M et al. – Review describes the characteristics of antibody against phosphatidylethanolamine1 (aPE), a zwitterionic phospholipids, and the recent evidence that aPE are correlated with the main clinical features of antiphospholipid syndrome (APS), notably, in the absence of the laboratory criteria of this syndrome.

The isolated presence of aPE in clinical APS may be used as laboratory markers of ‘seronegative APS’, which refers to patients persistently negative for these antibodies despite a clinical picture that is highly suggestive of this syndrome. Nevertheless, future studies are required to standardise aPE assays to support the clinical relevance of these antibodies.

<< Previous
Measurement of change in function and disability in...

Next >>
Adalimumab in ankylosing spondylitis: an evidence-based review of...